Participated · Series A · Nov 2025

TandemAI operates a fully integrated drug discovery engine that blends generative AI, molecular dynamics, quantum-mechanics simulations, and an AI-powered SaaS platform called TandemViz with expansive chemistry and biology laboratories. This computation-first approach spans target prediction through clinical candidate nomination and has already produced more than ten high-value drug candidates now in or approaching clinical trials. The company serves a network of over 150 global pharmaceutical partners, helping advance more than 50 innovative pipelines and achieving 10× revenue growth since launch. A recent merger with Perpetual Medicines added deep expertise in peptide and antibody-peptide conjugate discovery, broadening TandemAI’s modality coverage. The firm employs more than 300 professionals and maintains R&D hubs in New York, Boston, and China. Founded in October 2021, TandemAI has raised more than $80 million to date to scale its AI models, wet-lab capacity, and commercial reach.

Led · Series B · Aug 2025

SpeedBot Robotics focuses on "AI + 3D vision", industrial intelligent software, and smart factory solutions to automate visual inspection and measurement tasks. Its R&D team has developed a portfolio of intelligent measurement products and a dual-driven solution matrix that integrates intelligent manufacturing and measurement across stamping, welding, painting, and final assembly. The company serves heavy machinery, automotive, and new energy industries, addressing manual inspection inefficiencies in workpiece and finished-product inspection. SpeedBot has grown from just over a dozen employees into a leading player in AI machine vision and industrial intelligent software within six years. It has increased R&D investment, opened a Shanghai R&D center in August 2022, and established subsidiaries in Germany, Singapore, Vietnam, and Canada to accelerate overseas expansion and commercialization. The company is preparing for entry into the capital markets and plans to use new capital to advance embodied industrial intelligence products and expand in the shipbuilding and lithium battery sectors.

Participated · Series B · Jan 2024

光鉴科技 is a high-tech startup originating from Silicon Valley that develops a proprietary 3D-vision solution based on advanced nanophotonics. The company holds independent intellectual property for its new approach. Its solution emphasizes low cost, low power consumption, and a mature supply chain to enable large-scale deployment. Target markets include smart terminals, AR/VR, smart security, robotics vision, autonomous driving, and automated medical applications, forming a multi‑billion‑dollar market. The company recently completed a RMB 200 million B round. The proceeds will be used to expand the business.

Participated · Series A · Nov 2021

Raydiant Oximetry is a venture-backed, clinical-stage medical device company based in San Ramon, California, focused on improving outcomes for mothers and babies during childbirth. The company was founded by Neil P. Ray, MD, and has developed Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy™, a vacuum-induced surgical tool for OB/GYN applications. Raydiant’s core product work centers on fetal pulse oximetry to better identify fetal distress and potentially avoid medically unnecessary C-sections. The company plans to use prize funding and development sprints to further advance and de-risk its technologies for clinical adoption. Raydiant frames its innovations as transformative for monitoring practices during labor and delivery and is advancing through clinical-stage development and expert evaluation. Raydiant Oximetry, based in San Ramon, CA and founded by Neil P. Ray, develops two clinical-stage technologies: Lumerah™, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy™, a surgical device to quantify blood loss, treat uterine atony and prevent postpartum hemorrhage after C-section. The company is focused on improving outcomes for mothers and babies during childbirth. Raydiant plans to use its new funding to support two clinical studies of Lumerah and Daisy being conducted at Eastern Virginia Medical School under Dr. George Saade. The studies aim to generate clinical evidence to validate performance and safety in labor and delivery settings. Raydiant is pursuing regulatory and clinical pathways typical for medical devices as it advances these technologies through clinical evaluation. The company recently raised extension funding to advance those clinical programs. Raydiant Oximetry is a clinical-stage medical device company based in San Ramon, CA focused on improving women’s and neonatal health. Its core product is LUMERAH™, a non-invasive fetal oximeter designed to detect fetal distress during labor and delivery. LUMERAH is an investigational medical device and is not currently approved for commercial sale. The company is led by founder and CEO Neil Ray, MD. Raydiant raised $5M in a Series A2 financing and intends to use the funds to complete a clinical study at the University of Texas Medical Branch in Galveston. The UTMB study, with Dr. George Saade as principal investigator, is part of clinical research supported by the NIH Maternal‑Fetal‑Medicine Network to advance validation of the device. Raydiant Oximetry is a Mountain View, California medical device company that has developed a noninvasive fetal monitor to directly measure a baby’s oxygenation during pregnancy and childbirth. Founded in 2016 and led by CEO Dr. Neil P. Ray, the company is in residence at the Fogarty Institute for Innovation. It has demonstrated feasibility of the technology in pregnant women through an IRB‑approved study and validated results in animal models. Raydiant holds two issued patents protecting the core technology and expects up to ten more patents over the next 36 months. The company raised $1M in seed funding and intends to use the proceeds to build a subsequent prototype with improved accuracy and reliability.